Kuros BiosciencesCSBTF 71 3-Year ROIIC % is 43.62 as of Dec. 2025, which is 150% above its 10-year median of 17.47. GuruFocus rates CSBTF with a GF Score™ of 71/100 and a GF Value™ of $48.29 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 800 Medical Devices & Instruments companies, Kuros Biosciences ranks better than 81.75% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Kuros Biosciences's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 43.62%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Kuros Biosciences's 3-Year ROIIC % or its related term are showing as below:
CSBTF's 3-Year ROIIC % is ranked better than 81.75% of 800
companies
in the Medical Devices & Instruments industry
Industry Median: 1.285
vs CSBTF: 43.62
Kuros Biosciences (OTCPK:CSBTF) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Kuros Biosciences 3-Year ROIIC % Related Terms
Kuros Biosciences 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Kuros Biosciences's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Kuros Biosciences's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kuros Biosciences 3-Year ROIIC % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Kuros Biosciences's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Kuros Biosciences's 3-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Kuros Biosciences (CSBTF) has a 3-Year ROIIC % of 43.62 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Kuros Biosciences and its competitors. This is 150% above median its historical median of 17.47. According to the industry distribution chart, Kuros Biosciences ranks #146 out of 800 companies in the Medical Devices & Instruments industry, placing it in the top 18.2%.
Is Kuros Biosciences' 3-Year ROIIC % too high?
Kuros Biosciences' current 3-Year ROIIC % of 43.62 is 150% above median its 10-year median of 17.47. The Medical Devices & Instruments industry median 3-Year ROIIC % is 1.29. Kuros Biosciences' value of 43.62 is 3294.6% above this industry median. Based on the distribution chart, Kuros Biosciences ranks #146 out of 800 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Kuros Biosciences has a GF Score™ of 71/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Kuros Biosciences' 3-Year ROIIC % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Kuros Biosciences ranks #146 out of 800 companies for 3-Year ROIIC %. This places Kuros Biosciences in the top 18% of its industry — outperforming the majority of peers. The industry median 3-Year ROIIC % is 1.29. Kuros Biosciences' value of 43.62 is 3294.6% above this benchmark. While the company's 10-year median is 17.47 vs. the industry median of 1.29, Kuros Biosciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Medical Devices & Instruments company?
The median 3-Year ROIIC % among Medical Devices & Instruments companies is 1.29, based on 800 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kuros Biosciences's current 3-Year ROIIC % of 43.62 is 3294.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Kuros Biosciences and its competitors. For the Medical Devices & Instruments industry, the median 3-Year ROIIC % is 1.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kuros Biosciences's current 3-Year ROIIC % is 43.62, which is 150% above median its own 10-year median of 17.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kuros Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Kuros Biosciences (CSBTF) is currently considered Significantly Undervalued. The stock's GF Value™ is $48.29, compared to a current price of $22.72 — trading 53% below its estimated fair value. The current 3-Year ROIIC % is 43.62, which is 150% above median its 10-year median of 17.47 and 3294.6% above the Medical Devices & Instruments industry median of 1.29. Kuros Biosciences' overall GF Score™ is 71/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Kuros Biosciences (CSBTF), the current 3-Year ROIIC % is 43.62 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kuros Biosciences (CSBTF) Overvalued in 2026?
Based on GuruFocus' analysis, Kuros Biosciences stock appears to be undervalued.
The current stock price of $22.72 is trading 53% below its estimated GF Value™ of $48.29.
GuruFocus considers Kuros Biosciences to be Significantly Undervalued.
Key valuation signals for CSBTF:
3-Year ROIIC %: 43.62 (150% above median its 10-year median of 17.47)
GF Value™: $48.29 vs. price of $22.72 (53% below fair value)
Industry Position: 3294.6% above the Medical Devices & Instruments median (#146 of 800)
No single metric tells the full story. See the CSBTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kuros Biosciences Ltd is a Swiss-based biotech company, focused on developing and commercializing biologic bone graft technologies for musculoskeletal applications, particularly in spine, trauma, extremities, and oncology. It has two reportable segments: i) Medical Devices: This segment includes products such as MagnetOs and Attrax, which are biphasic calcium phosphate (BCP) bone grafts that mimic the porous, trabecular structure of cancellous bone. ii) Legacy Portfolio: This segment includes all non-core products (including Checkmate licensing) that are outside the Group's primary therapeutic focus. The majority of the company's revenue is derived from the Medical Devices segment. Geographically, it generates the maximum revenue from the United States of America.
71GF Score
Get the complete analysis for CSBTF
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSBTF has been successfully added to your 
